Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Bayer touted its experimental cancer drug anetumab ravtansine as a $2 billion-plus peak earner in the making for the pharma company. And it just flopped in its first mid-stage study — this one focused on rare cases of mesothelioma.
Bayer will detail the data later, but investigators say the drug flunked a Phase II study with a primary endpoint of progression free survival. The drug is also currently in 6 other early stage studies for a variety of tumor types.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters